Table of Contents

company-logo

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Alligator Bioscience Dividend Announcement

• Alligator Bioscience does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Alligator Bioscience dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Alligator Bioscience Dividend History

Alligator Bioscience Dividend Yield

Alligator Bioscience current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Alligator Bioscience stock? Use our calculator to estimate your expected dividend yield:

Alligator Bioscience Financial Ratios

P/E ratio-0.74
PEG ratio-0.06
P/B ratio-2.43
ROE797.45%
Payout ratio0.00%
Current ratio0.35
Quick ratio0.35
Cash Ratio0.29

Alligator Bioscience Dividend FAQ

Does Alligator Bioscience stock pay dividends?
Alligator Bioscience does not currently pay dividends to its shareholders.
Has Alligator Bioscience ever paid a dividend?
No, Alligator Bioscience has no a history of paying dividends to its shareholders. Alligator Bioscience is not known for its dividend payments.
Why doesn't Alligator Bioscience pay dividends?
There are several potential reasons why Alligator Bioscience would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Alligator Bioscience ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Alligator Bioscience has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Alligator Bioscience a dividend aristocrat?
Alligator Bioscience is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Alligator Bioscience a dividend king?
Alligator Bioscience is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Alligator Bioscience a dividend stock?
No, Alligator Bioscience is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Alligator Bioscience stocks?
To buy Alligator Bioscience you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Alligator Bioscience stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.